Yves Fradet

Université Laval, Hôtel-Dieu de Québec

Papers

2

Total Citations

8

H-Index

2

About

Dr. Yves Fradet is a leading urologic oncologist whose research centers on prostate cancer surgery, patient outcomes, and evidence-based clinical practice. He has made major contributions by critically evaluating surgical innovations and perioperative management in radical prostatectomy. His highly cited 2013 paper, "Arguments against investing widely in robotic prostatectomy in Canada," challenged prevailing trends by arguing that surgical expertise—not technology—drives patient outcomes, sparking important debate in the field. With over 5 citations, this work has influenced healthcare policy and surgical training priorities. More recently, Dr. Fradet investigated the effects of omega-3 fatty acid supplementation on perioperative blood loss and complications after radical prostatectomy (2021, 3 citations), addressing a common clinical dilemma where patients are often advised to discontinue supplements without strong evidence. His work highlights the potential benefits of long-chain omega-3s while questioning routine preoperative cessation. Dr. Fradet’s research is characterized by its direct clinical relevance and willingness to challenge dogma, making him a respected voice in urologic oncology. His contributions continue to shape how surgeons approach prostate cancer treatment, emphasizing patient-centered, evidence-based care.

Research Focus

Key Achievements

2
H-Index
2
Papers
8
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Arguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise
5 citations · 2013
📈 Most Prolific Year: 2013 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Université Laval, Hôtel-Dieu de Québec

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago